University of Hawaii
Bile Acid-microbiota Cross-talk and Its Effects on Liver Cancer
Title: Bile Acid-microbiota Cross-talk and Its Effects on Liver Cancer
Dr. Jia joined the University of Hawaii Cancer Center in 2013 as the Associate Director for Shared Resources. Previously, he spent about 5 years as a Professor at University of North Carolina at Greensboro and Co-Director of UNCG Center for Translational Biomedical Research. Prior to his appointment with UNCG, Dr. Jia worked in China for 10 years, as Professor and Executive Vice Dean at College of Pharmaceutical Science, Tianjin University, and Professor and Vice Dean for Research, School of Pharmacy, Shanghai Jiao Tong University.
Dr. Jia's research interest involves carbon source metabolism and its regulation in cancer cells as well as the molecular mechanisms that link metabolic disruptions in gut microbial-host co-metabolism to metabolic disorders and gastrointestinal cancer. Several research projects are being conducted in Dr. Jia's group to decipher the complex metabolic interactions in gut-liver-brain axis and regulation of cancer cell metabolism.
In addition, Dr. Jia directs a well-recognized metabolomics laboratory (currently as one of the UHCC shared resources). Over the past 13 years, his lab has developed a number of metabolomics technologies and protocols, focusing on the quantitative analysis of endogenous small-molecule metabolites and trace elements from biological specimens including blood, urine, saliva, and tissues of experimental animals and human subjects. Many of these technologies have been applied in clinical and translational research, involving (1) unbiased metabolic profiling and data mining, metabolite annotation and biological interpretation using combined high sensitivity, high throughput LC-MS-MS and GC-MS platforms; (2) targeted and quantitative analysis of metabolic rates and pathways using isotope labeled common substrates such as glucose and cholate; (3) classification and prediction of disease phenotypes based on their unique metabolic signatures and biomarkers for patient stratification and personalized treatment; and (4) novel methodologies to delineate the host-gut microbe co-metabolism of diets and multi-component herbal medicines, such as poly-pharmacokinetics and gut microbial metabolomics.
Jia, W.*, Li HK, Zhao LP, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nature Reviews Drug Discovery, 2008, 7(2):123-9. PMID:18239669 ( IF 57.000 )
Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia, W.*, Pettersson S. Host-gut microbiota metabolic interactions. Science, 2012, 336(6086): 1262-7. PMID:22674330
Chen, WL, Wang, YY, Zhao, AH, Xia, L, Xie, GX, Su, MM, Zhao, LJ, Liu, JJ, Qu, C, Wei, RM, Rajani, C, Ni, Y, Cheng, Z, Chen, Z, Chen, SJ, Jia, W.*. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential, Cancer Cell, 2016, 30(5), 779-791, 2016. PMID: 27746145 ( IF 27.407 )
Zheng XJ, Zhao AH, Xie GX, Chi Y, Zhao LJ, Li HK, Wang CR, Bao YQ, Jia WP, Luther M, Su MM, Nicholson JK, Jia, W.*. Melamine-Induced renal toxicity is mediated by the gut microbiota. Science Translational Medicine, 2013, 5(172):172ra22. PMID:23408055 ( IF 16.796 )
Jia, W.*, Xie, G.X. Jia, W.P. Bile acids and microbiome cross-talk and its impact on gastrointestinal inflammation and carcinogenesis. Nature Reviews Gastroenterology and Hepatology. 2018. doi:10.1038/nrgastro.2017.119., [Epub ahead of print] ( IF 13.678 )
Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL, Li JM, Mi JQ, Zhu YM, Liu YF, Wang YY, Jin J, Huang H, Wu DP, Li Y, Yan XJ, Yan JS, Li JY, Wang S, Huang XJ, Wang BS, Chen Z, Chen SJ, Jia, W.*. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood. 2014 Sep 4;124(10):1645-54. doi: 10.1182/blood-2014-02-554204. Epub 2014 Jul 8. ( IF 13.164 )
Qiu YP, Cai GX, Zhou BS, Li D, Zhao AH, Xie GX, Li HK, Cai SJ, Xie D, Huang CZ, Ge WT, Zhou ZX, Xu L, Jia WP, Zheng S, Yen Y, Jia, W.*.A distinct metabolic signature of human colorectal cancer with prognostic potential, Clinical Cancer Research, 2014, 20(8), 2136-2146. PMID: 24526730 ( IF 9.619 )
Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, Chen T, Qu C, Rajani C, Dong B, Li D, Jia, W.*. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol. 2017 Dec 14;15(1):120. doi: 10.1186/s12915-017-0462-7. ( IF 6.779 )
Xie, GX, Wang, XN, Huang, FJ, Zhao, AH, Chen, WL, Yan, JY, Zhang, YJ, Lei, S, Ge, K, Zheng, XJ, Liu, JJ, Su, MM, Liu, P, Jia, W.*. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. International Journal of Cancer, 2016, 139(8), 1764-1775. PMID: 27273788 ( IF 6.513 )
W. Jia, Principal Investigator
"Gut microbiota mediated bile acid alterations in hepatic carcinogenesis"
08/01/15 - 07/31/20
W. Jia, Co-Investigator (PI: Brouwer)
NIH/NIGMS 2R01GM041935 - 22 / P140RO
"Altered hepatic disposition of anionic drugs-mechanisms"
09/01/14 - 8/31/19
W. Jia, Co-Investigator (PI: Holcombe)
NIH/NCI P30 CA071789
"Cancer Center Support Grant (CCSG): University of Hawaii Cancer Center"
07/01/12 – 08/31/17
W. Jia, Co-Investigator (PI: Cheng)
NIH/NCI 1 P01 CA154295-01A1
"Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy"
04/01/12 - 03/31/17
W. Jia, Principal Investigator
Nestle Institute of Health Sciences Ltd. Award 007184-00002
"Microbiome metabonomics: monitoring mammalian - gut microbial co- metabolism in human plasma, urine and stools"
You have registered successfully, the registration information and attention has been sent to the contact and the participants of the mailbox, please note that check. If not received, please contact the general meeting